Tag: Attorney M. David Shapiro
Sarasota Injury Lawyer David Shapiro Named Top 10 Plaintiff’s Attorney by Attorney and Practice Magazine
SARASOTA, Fla., Sept. 18, 2017 (SEND2PRESS NEWSWIRE) -- ATTORNEY AND PRACTICE Magazine has awarded David Shapiro Esq., with a Top 10 Plaintiff's Attorney Designation. David Shapiro Esq., founding partner of the Sarasota based personal injury law firm Shapiro Goldman Babboni Fernandez & Walsh, has been awarded a Top 10 Plaintiff's Attorney Designation by the popular legal industry and legal news website Attorney and Practice Magazine.
Sarasota Attorney David Shapiro Named Best Lawyer 5th Consecutive Year
SARASOTA, Fla., June 9, 2017 (SEND2PRESS NEWSWIRE) -- For a fifth year in a row, personal injury and civil trial attorney M. David Shapiro, of Shapiro Goldman Babboni Fernandez & Walsh has been accepted as a member of Best Lawyers. Highly regarded within the legal industry, Best Lawyers has been cited as one of the most respected peer review publication in the legal profession.
David Shapiro Named 2017 Florida 10 Best Attorney by The American Institute of Personal Injury Attorneys
SARASOTA, Fla., April 10, 2017 (SEND2PRESS NEWSWIRE) -- Attorney David Shapiro of the civil trial law firm Shapiro Goldman Babboni Fernandez & Walsh has been inducted into the 2017 10 Best Attorney's by the American Institute of Personal Injury Attorneys (AIOPIA). Shapiro is an AV-rated civil trial lawyer, the highest rating awarded to litigation attorneys.
Attorney M. David Shapiro Advises Consumers about Post-Crash Insurance Rate Hikes
SARASOTA, Fla., Dec. 8, 2016 (SEND2PRESS NEWSWIRE) -- M. David Shapiro, founding partner of the personal injury and civil trial law firm Shapiro Goldman Babboni & Walsh, has offered consumers insight into auto insurance rate-hikes that can occur after being involved in an accident.
Sarasota Attorney M David Shapiro Comments on Landmark $70 Million ADHD Drug Risperdal Lawsuit
SARASOTA, Fla., July 28, 2016 (SEND2PRESS NEWSWIRE) -- The Sarasota Florida attorney commented after a Philadelphia jury returned a verdict of $70 million against Johnson and Johnson for failing to warn of the risks associated for taking Risperdal. The case involved a sixteen-year-old boy who developed breast from the medication prescribed for attention deficit disorder (ADHD).